Clinical Investigations

Size: px
Start display at page:

Download "Clinical Investigations"

Transcription

1 Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen Ji Lin, MD; Gao Run Lin, MD Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking UnionMedicalCollege, Beijing, China Address for correspondence: Qiao Shu Bin, MD Department of Cardiology Cardiovascular Institute and Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 167 BeiLiShi Rd , China Background: Stents had been demonstrated to be safe and effective in the treatment of severe coronary artery disease (CAD); however, the current knowledge on percutaneous coronary intervention (PCI) in treating patients requiring 2 or more stents placements is still limited. Hypothesis: Patients who required 2 or more stents might have worse clinical outcomes. Methods: A total of 2371 patients who underwent stenting were divided into a single stenting group (n = 1233) and a multiple stenting group (n = 1138). We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and stent thrombosis during 1-year follow-up. Results: The 1-year unadjusted cumulative incidence of major adverse cardiac events was 7.7% in the multiple stenting group and 5.4% in the single stenting group (P = 0.02 by log-rank test). After adjustment, there was a trend toward a lower rate of 1-year major adverse cardiac events in the single stenting group than in the multiple stenting group (P = 0.09). A nonsignificant trend was also detected in favor of the single stenting group, as compared with the multiple stenting group, at the rate of acute myocardial infarction (1.3% vs 1.7%, P = 0.89) and at the rate of target-vessel revascularization (4.5% vs 5.4%, P = 0.08). Conclusions: Although the use of a single stent in coronary artery disease has less incidence of adverse cardiac events at 1 year as compared with the use of multiple stents, the difference was not statistically significant. Introduction Since the era of balloon angioplasty, stents had been demonstrated to be substantially safe and effective in the treatment of severe coronary artery disease (CAD) in the field of interventional cardiology. 1 Use of drug-eluting stents (DES) has been demonstrated to further reduce in-stent restenosis and the need for new revascularization procedures compared with conventional bare-metal stents (BMS). 2,3 Even in patients with multivessel diseases, only 1 lesion per patient was treated, with up to 2 stents per patient. 4,5 It is unrealistic to expect the design and conduct of controlled trials to include all possible clinical presentations, alone or in combination, such as multivessel disease and multiple lesions. In the daily practice of percutaneous coronary intervention (PCI), the proportions of patients with multi-lesions or multivessel diseases who had to be implanted with multiple stents or with different types of stents are increasing. In some conditions, lesions executed with stent implantation or treated with more than 1 stent might not be necessary. Furthermore, the current knowledge on PCI in treating patients requiring 2 or more stent placements is still limited. To further pursue this interesting area in the real-world, we conducted this study to analyze the patients who underwent PCI with implantation of stents and compared the clinical outcomes of single stents with multiple stent implantation. Methods Study Design and Patient Population Between April 2004 and April 2005, 2371 patients in the Fuwai hospital underwent PCI with stent implantation. Based on the number of coronary stents implanted, patients were assigned to a single stenting group (n = 1233) and a multiple stenting group (n = 1138). Interventional strategy and device use, including type of stent, were left to the discretion of the attending physicians. Antiplatelet treatment was prescribed according to current standards of treatment, including lifelong aspirin for all patients, 1 month of ticlopidine (250 mg BID) or clopidogrel (75 mg/day) treatment for patients treated with BMS, and the same treatment for at least 3 months for patients treated with DES. Definitions and Follow-Up The primary endpoint of the survey was the occurrence of major adverse cardiac events (MACE), defined as: (1) death from cardiac causes, (2) nonfatal acute myocardial infarction (MI), and (3) target-vessel revascularization (TVR). Myocardial infarction (MI) during follow-up was diagnosed by local cardiologists at the hospital of admission according to standard criteria (rise in the creatine kinase level to more than twice the upper limit of normal with an Received: July 19, 2008 Accepted with revision: August 18, 2008 E33

2 Clinical Investigations continued increased creatine kinase-mb [CK-MB] and newly developed Q waves). Target-vessel revascularization was defined as a reintervention (coronary artery bypass graft [CABG] or PCI) driven by any lesion located in the same epicardial vessel. The protocol of our study did not include routine angiography for any subgroup of patients; therefore, virtually all reinterventions can be considered clinically driven. Clinically driven repeat revascularization was defined as any intervention motivated by a significant luminal stenosis (>50% diameter stenosis) in the presence of anginal symptoms and/or proven myocardial ischemia in the target vessel territory by noninvasive testing. Stent thrombosis was defined according to a standardized definition proposed by the Academic Research Consortium (ARC). 6 Follow-up was obtained directly and independently through analysis of the hospital discharge records and the mortality registries. During each patient s hospital stay, we recorded all adverse events during follow-up visits at 6 months and at 12 months; we also recorded all serious adverse cardiac events (death from cardiac causes, nonfatal acute MI, TVR). Statistical Analysis Continuous variables were expressed as mean±sd and were compared with the Student unpaired t test. Categorical variables were expressed as counts and percentages, and the χ 2 test was used for comparison. The cumulative incidence of adverse events was estimated according to the Kaplan-Meier method and compared by the log-rank test. Because of the observed differences in baseline characteristics between the treatment groups, a propensity score analysis was performed by use of a logistic regression model for treatment with single stenting vs multiple stenting. A multiple logistic regression model was constructed with the following variables considered as candidates: age, gender, hypertension, hyperlipidemia, peripheral vascular disease, diabetes mellitus, history of MI, smoking status, prior PCI, prior CABG, number of vessel disease, only use of DES, American College of Cardiology/American Heart Association (ACC/AHA) type C lesion, left main stenting, ostial lesion, chronic total occlusion >3 months, bifurcation, instent restenosis, and bypass graft lesions. The logistic model by which the propensity score was estimated showed good predictive value (C-statistic = 0.811), and calibration characteristics by the Hosmer-Lemeshow test (P = 0.13). The score was then incorporated into subsequent proportionalhazards models as a covariate. Multivariable analyses were performed to identify independent predictors of MACE and TVR using the following variables: age, sex, hypertension, hyperlipidimia, peripheral vascular disease, diabetes mellitus, prior PCI, prior CABG, prior MI, number of vessel disease, number of stents deployed, only use of DES, ACC/AHA type C lesion, left main stenting, ostial lesion, chronic total occlusion >3 months, bifurcation, instent restenosis, and bypass graft lesions. Multiple-variable predictors were chosen by a stepwise procedure with an entry criterion of 0.10 with a stay criterion P values of <0.05 were considered to indicate statistical significance. All analyses were performed with the SAS 9.1 system (SAS Institute, Inc., Cary, NC). Results Baseline Characteristics and Procedural Results Between April 2003 and April 2004, 1233 patients were treated with single stent (1360 lesions treated, 1233 stents implanted), and 1138 patients were treated with 2 stents (2573 lesions treated, 2791 stents implanted), with all patients having been visited at 6-months and 12-months follow-up. A number of differences were observed in demographics (Table 1) and in angiographic or procedural characteristics (Table 2) between the 2 groups. Being male and having hyperlipidemia were more frequently observed in the multiple stenting group, which also showed higher rates Table 1. Baseline Clinical Characteristics of Patients Treated with a Single Stent or Multiple Stents Variable Single Stent (n = 1233) Multiple Stents (n = 1138) P Value Male Age 57.6± ± Hypertension Diabetes mellitus Hyperlipidemia Prior PCI Prior CABG Prior myocardial infarction Current smoker Ejection fraction 58.0± ± Clinical presentation Stable angina pectoris a Unstable angina pectoris Acute MI Values are percent or mean±sd. a Including silent ischemia. Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; MI, myocardial infarction. E34

3 Table 2. Angiographic Lesion Characteristics and Procedural Details of the Study Groups Variable Single Stent (n = 1360) a Multiple Stents (n = 2573) a P Value Treated coronary vessel Left anterior descending <0.001 Left circumflex <0.001 Right <0.001 Left main Bypass graft No. of lesions treated 1.1± ±0.8 <0.001 No. of implanted stents 1±0 2.6±0.8 <0.001 No. of vessels diseased 1.7± ±0.7 <0.001 Type C <0.001 Bifurcation Ostial lesion Chronic total occlusion >3 mo In-stent restenosis lesion Stent type 0.27 Multi-Link Drive Cypher Select Taxus Express Firebird Other DES Average lesion length, b mm 17.0± ±12.3 <0.001 Average stent length, mm 21.1± ±14.6 <0.001 Reference vessel diameter, b mm 3.2± ±0.5 <0.001 MLD, b mm 0.4± ± Only use of DES c <0.001 Procedure complications c,d Procedure success c Values are percent or mean±sd. a Total number of lesions. b Visual estimation. c Referred to 1233 patients in the single stenting group and 1138 patients in the multiple stenting group. d Indicates the complications that occurred during or as a result of a procedure which includes systemic and peripheral complications such as myocardial infarction, death, arrhythmia, coronary perforation, coronary artery dissection, contrast nephropathy, vascular complications, and so forth. Abbreviations: MLD, minimum lumen diameter; DES, drug-eluting stents; Multi-Link (Guidant, CA, USA); Drive (Medtronic, Inc.); Cypher Select (Johnson & Johnson); Taxus Express 2 (Boston Scientific); Firebird (MicroPort). E35

4 Clinical Investigations continued of smoking as well. The multiple stents were also implanted more than single stents in the treatment of the right coronary artery, left circumflex coronary artery, type C lesions, chronic total occlusion >3 months, small vessels, and long lesions. The proportion of type of stent and DES were similar between the 2 groups; however, patients who only used DES were more frequent in the single stenting group. Procedural success was achieved in >98% and complications were seen in <1% of the procedures in both groups. Clinical Outcomes The 6-months and 1-year unadjusted cumulative incidence of MACE were shown in Table 3. There were no significant differences between the single stenting group and the multiple stenting group in 6-months cumulative incidence of death, acute myocardial infarction (AMI), and TVR. However, the 1-year cumulative incidence of MACE (death, AMI, or TVR) was significantly lower in the single stenting group than in the multiple stenting group (3.2% vs 4.9%, Table 3. One-Year Unadjusted and Propensity Score-Adjusted Cumulative Incidence of MACE in the Study Groups Variable Single Stent (n = 1233) Multiple Stents (n = 1138) P Value Unadjusted Follow-up at 6 mo MACE Death from cardiac causes AMI TVR CABG PCI Stent thrombosis Acute and subacute (<30 d) Late (30 d to 6 mo) Follow-up at 12 mo MACE Death from cardiac causes AMI TVR CABG PCI Propensity score-adjusted Follow-up at 6 mo MACE Death from cardiac causes AMI TVR CABG PCI Stent thrombosis E36

5 Table 3. (Continued) Variable Single Stent (n = 1233) Multiple Stents (n = 1138) P Value Acute and subacute (24 h to 30 d) Late (30 d to 6 mo) Follow-up at 12 mo MACE Death from cardiac causes AMI TVR CABG PCI Values are percentages. P values are by log-rank test for unadjusted incidence and by multiple logistic regression model for propensity score-adjusted incidence. Abbreviations: MACE, major adverse cardiac events; AMI, acute myocardial infaction; TVR, target-vessel revascularization; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention. P = 0.04). Notably, the incidence of angiographic stent thrombosis did not appear significantly different in the 2 groups (0.5% vs 0.8%, P = 0.35). At 1 year, the cumulative incidence of death and AMI was also similar in the 2 groups. Patients treated with a single stent had significantly less TVR (3.9% vs 6.1%, P = 0.01) and MACE (5.4% vs 7.7%, P = 0.02) at 1 year than patients treated with multiple stents. To adjust for differences in baseline clinical and angiographic characteristics, a propensity score analysis of the data was carried out as previously described. As shown in Figure 1 and Table 3, the 1-year incidence of MACE was lower in the single stenting group compared with the multiple stenting group (6.0% vs 7.3%; hazard ratio [HR]: 0.78, 95% confidence interval [CI]: , P = 0.09), and this was driven mainly by the reduction in TVR (4.5% vs 5.4%, HR: 0.71, 95% CI: , P = 0.08). Although trends were observed in favor of the single stenting group, none of these differences were significant. Conversely, the 1-year cumulative risk of death and MI were similar in the 2 cohorts of patients. Predictors of Adverse Events Table 4 lists the multivariate predictors of 1-year adverse events. In the overall population, the factors associated with 1-year MACE were prior PCI, prior CABG, type C lesion, ostial lesion, and only use of DES. The predictors of 1-year TVR were being male, prior PCI, prior CABG, the number of stents deployed, and only use of DES. Cumulative probability of events, % Hazard ratio 0.78 (95% C10.55 to 1.12) p =0.09 Multiple stenting 73% Single stenting 6.0% Days Figure 1. Propensity score-adjusted 1-year cumulative incidence of major adverse cardiac events (MACE) in patients treated with single stent and in patients treated with multiple stents. Discussion The major finding of this study is that in a real-world complex population, the cumulative incidence of MACE a composite of death from cardiac causes, nonfatal acute MI, and TVR at 1 year was 6.0% in the single stenting group and 7.1% in the multiple stenting group. The adjusted risk ratio was 0.78, which was not statistically significant. This was mainly due to the difference in the incidence of TVR (71% relative risk reduction), with no effect on mortality. There was also a trend in favor of the single stenting group in the rates of individual adverse events, but no single endpoint reached statistical significance. However, the available data comparing these 2 strategies of stenting in elective PCI are limited and controversial. 7 9 In the pre-des period, Pan et al compared the clinical outcome of patients with long diffuse stenosis treated by 3 different stent strategies, which were composed of 1 single long stent, overlapped multiple E37

6 Clinical Investigations continued Table 4. Clinical, Procedural, and Angiographic Multivariable Predictors of 1-Year MACE and TVR Variable HR 95% CI P Value MACE TVR Only use of DES <0.001 Prior PCI Prior CABG Type C lesion Ostial lesion Male Only use of DES <0.001 Prior PCI Prior CABG <0.001 No. of implanted stents Abbreviations: MACE, major adverse cardiac events; DES, drug-eluting stents; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TVR, target-vessel revascularization. stents, and multiple non-overlapped stents strategy; the 2- year cumulative incidence of MACE (death, acute MI, or repeat revascularization) were similar in 3 groups. 7 In the DES period, another retrospective analysis showed that the patients who required 3 sirolimus-eluting stents (SES) implantations had significantly higher rates of MI, TVR, and MACE compared with the patients with the same risk profiles who underwent PCI with a single SES implantation. 8 There are a number of possible explanations for the differences between the results of this study and those of previous studies. First, we compared a strategy of usage of multiple stents with the usage of a single stent in the daily practice of PCI, but not a specific type of stent. Second, 2 study groups were consecutively included over a total period of only 1 year, some important differences were noted in the interventional strategy applied, which may somewhat limit an unbiased comparison between them. However, it is worth noting that not all differences would be traditionally expected to increase the incidence of late complications. Nevertheless, the treatment effect of single stenting was not significant higher than multiple stenting after propensity score-adjustment. Third, the study design did not include angiographic follow-up. Recurrent stenosis observed during routine follow-up angiography could have led to reintervention without symptoms or objective evidence of ischemia, thus increasing the event rate. We did not observe a difference in the rates of stent thrombosis between our 2 study groups. Acute or subacute stent thrombosis occurred in 4 patients (0.3%) in the single stenting group and 6 patients (0.5%) in the multiple stenting group. We also found no evidence of an increase in the rate of late stent thrombosis, a topic that has recently caused concerninthedesera. 10 Recently, the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital registry and a meta-analysis study also demonstrated that the risk of stent thrombosis of DES was similar to BMS. 11,12 Therefore, whether the number of stents deployed and the type of stents used have an effect on stent thrombosis was not determined. We analyzed the predictors of clinical outcomes in all patients. These analyses confirmed that the use of only DES is independently associated with a reduction in MACE and TVR in the general population. We also showed the predictive value of prior PCI, prior CABG, and a number of angiographic and procedural features, such as type C lesion, ostial lesion, with regard to MACE or TVR (Table 4). Furthermore, we demonstrated that the number of stents deployed was an independent risk factor of TVR, but not of MACE, which was consistent with other observations. 11,13 Our findings might indicate the number of stents deployed mainly effect the need for repeated revascularization procedures. Study Limitations This study suffers limitations of observational nonrandomized studies. On the other hand, it carries important and complementary information derived from real-world practice, given the inclusion of patients and lesions often excluded from randomized trials. The present study is also a single-center experience and lacks systematic angiographic follow-up. Furthermore, it is unlikely that a randomized study will be conducted in the context in which this study was performed, with virtually no exclusion criteria. Finally, we performed a propensity analysis to overcome the pitfalls of nonrandomized comparisons of health care interventions, which are known to be a valuable approach for taking adequately into account the potential confounding effect attributable to between-groups imbalances. 14 Conclusions In conclusion, our study did not show a significant benefit associated with single stenting in coronary artery disease, as compared with multiple stenting in daily practice. However, the use of multiple stents in PCI should be undertaken with great caution. References 1. Popma JJ, Kuntz RE, Baim DS. A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation. 2002;106: Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. NEnglJMed. 2002;346: E38

7 3. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. NEnglJ Med. 2004;350: Morice MC, Serruys PW, Sousa JE, et al. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. NEnglJMed. 2002;346: Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimuseluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109: Mauri L, Hsieh WH, Massaro JM, Ho KK, D Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. NEnglJMed. 2007;356: Pan M, Suárez de Lezo J, Medina A, et al. Influence of stent treatment strategies in the long-term outcome of patients with long diffuse coronary lesions. Catheter Cardiovasc Interv. 2003; 58: Chu WW, Kuchulakanti PK, Rha SW, et al. Impact of three or more versus a single sirolimus-eluting stent on outcomes in patients who undergo percutaneous coronary intervention. Am J Cardiol. 2006;97: Chu WW, Kuchulakanti PK, Torguson R, et al. Impact of three or more sirolimus-eluting stents versus pacilitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006; 68: Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356: Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the real world : the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109: Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and pacilitaxel-eluting coronary stents. NEnglJMed. 2007;356: Kastrati A, Schümig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997; 30: Deeks JJ, Dinnes J, D Amico R, et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:iii x: E39

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large

More information

Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102

More information

Abstract Background: Methods: Results: Conclusions:

Abstract Background: Methods: Results: Conclusions: Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li

More information

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao) The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang

More information

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at

More information

The MAIN-COMPARE Study

The MAIN-COMPARE Study Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

PROMUS Element Experience In AMC

PROMUS Element Experience In AMC Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical

More information

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators

More information

LM stenting - Cypher

LM stenting - Cypher LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

PCI for In-Stent Restenosis. CardioVascular Research Foundation

PCI for In-Stent Restenosis. CardioVascular Research Foundation PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse

More information

Chinese Medical Journal 2008; 121(17): administered before the procedure. Results of coronary angiography and PCI procedures were assess

Chinese Medical Journal 2008; 121(17): administered before the procedure. Results of coronary angiography and PCI procedures were assess 1670 Original article Long term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years ZHANG Qi, XU Bo, YANG Yue-jin, QIAO Shu-bin,

More information

Influence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study

Influence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence

More information

Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus

Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039

More information

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,

More information

EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013

EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013 840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1

More information

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of

More information

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary

More information

Antiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria

Antiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria University of Groningen Antiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria IMPORTANT NOTE: You are advised to consult the publisher's

More information

Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome

Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome Journal of Geriatric Cardiology September 2009 Vol 6 No 3 157 Clinical Research Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome Hai-Ying Wang, 1 Jin-Bo

More information

Key Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent

Key Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke

More information

Rationale for Percutaneous Revascularization ESC 2011

Rationale for Percutaneous Revascularization ESC 2011 Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

DES in Diabetic Patients

DES in Diabetic Patients DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase

More information

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB

More information

Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China

Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001

More information

Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators

Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators I-LOVE-IT A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus- Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic

More information

Lessons learned From The National PCI Registry

Lessons learned From The National PCI Registry Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients

More information

Left Main and Bifurcation Summit I. Lessons from European LM Studies

Left Main and Bifurcation Summit I. Lessons from European LM Studies Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location

More information

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi

More information

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts

More information

Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era

Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era 3 Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era Pascalle S. Monraats, Willem R.P. Agema, Aeilko H. Zwinderman, Robbert J. de Winter, René

More information

Coronary drug-eluting stents (DES) were first approved

Coronary drug-eluting stents (DES) were first approved Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,

More information

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Supplementary Material to Mayer et al. A comparative cohort study on personalised Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass

More information

Supplementary Table S1: Proportion of missing values presents in the original dataset

Supplementary Table S1: Proportion of missing values presents in the original dataset Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)

More information

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol

More information

Controversies in Cardiac Surgery

Controversies in Cardiac Surgery Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm

More information

Journal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 47, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066

More information

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department

More information

Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations

Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations Journal of the American College of Cardiology Vol. 55, No. 16, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.02.008

More information

Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents

Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents ORIGINAL ARTICLE Korean J Intern Med 2013;28:72-80 Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents Jang-Won

More information

For Personal Use. Copyright HMP 2014

For Personal Use. Copyright HMP 2014 Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,

More information

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors

More information

Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis

Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting

More information

Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery

Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected

More information

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30. Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009

More information

Prevention of Coronary Stent Thrombosis and Restenosis

Prevention of Coronary Stent Thrombosis and Restenosis Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary

More information

Original Research Clinical Outcomes of Drug-Eluting Stents Compared with Bare Metal Stents in Our Routine Clinical Practice

Original Research Clinical Outcomes of Drug-Eluting Stents Compared with Bare Metal Stents in Our Routine Clinical Practice Hellenic J Cardiol 2008; 49: 132-138 Original Research Clinical Outcomes of Drug-Eluting Stents Compared with Bare Metal Stents in Our Routine Clinical Practice MOHAMMAD ALIDOOSTI, MOJTABA SALARIFAR, ALI

More information

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice

More information

Journal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.063

More information

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,

More information

PCI for Left Anterior Descending Artery Ostial Stenosis

PCI for Left Anterior Descending Artery Ostial Stenosis PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary

More information

PCI for Long Coronary Lesion

PCI for Long Coronary Lesion PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2

More information

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation ORIGINAL ARTICLE DOI 10.4070 / kcj.2010.40.1.10 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2010 The Korean Society of Cardiology Open Access The Effect of Cilostazol on Stent Thrombosis

More information

The MAIN-COMPARE Registry

The MAIN-COMPARE Registry Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation

Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation Journal of the American College of Cardiology Vol. 53, No. 17, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.01.050

More information

PCI for LMCA lesions A Review of latest guidelines and relevant evidence

PCI for LMCA lesions A Review of latest guidelines and relevant evidence HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd

More information

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique

More information

Stent Thrombosis in Bifurcation Stenting

Stent Thrombosis in Bifurcation Stenting Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,

More information

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal? HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic

More information

Bern-Rotterdam Cohort Study

Bern-Rotterdam Cohort Study Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz

More information

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro

More information

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES 1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)

More information

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT... May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...

More information

Journal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36.

Journal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36. Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.041

More information

DRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.

DRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are

More information

Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents

Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Thrombosis in Randomized Clinical Trials of Drug-Eluting s Laura Mauri, M.D., Wen-hua Hsieh, Ph.D., Joseph M. Massaro, Ph.D., Kalon

More information

Titan versus TAXUS Stents at 1 Year Clinical Outcome

Titan versus TAXUS Stents at 1 Year Clinical Outcome Original Article Titan versus TAXUS Stents at 1 Year Clinical Outcome Acta Cardiol Sin 2011;27:94 100 Interventional Cardiology One-Year Follow-Up after Percutaneous Coronary Intervention with Titanium-Nitride-Oxide-Coated

More information

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart

More information

Percutaneous Intervention of Unprotected Left Main Disease

Percutaneous Intervention of Unprotected Left Main Disease Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected

More information

Coronary Heart Disease. Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents

Coronary Heart Disease. Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents Coronary Heart Disease Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents Neil Sawhney, MD; Jeffrey W. Moses, MD; Martin B. Leon, MD; Richard E. Kuntz, MD; Jeffrey

More information

SeQuent Please World Wide Registry

SeQuent Please World Wide Registry Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4

More information

New Generation Drug- Eluting Stent in Korea

New Generation Drug- Eluting Stent in Korea New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the

More information

Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease

Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Original Article Acta Cardiol Sin 2009;25:1 6 Coronary Artery Disease Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Yung-Lung Chen,

More information

Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T

Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T Record Status This is a critical abstract of an economic

More information

Perspective of LM stenting with Current registry and Randomized Clinical Data

Perspective of LM stenting with Current registry and Randomized Clinical Data Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level

More information

Journal of the American College of Cardiology Vol. 57, No. 21, by the American College of Cardiology Foundation ISSN /$36.

Journal of the American College of Cardiology Vol. 57, No. 21, by the American College of Cardiology Foundation ISSN /$36. Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.033

More information

SKG Congress, 2015 EVOLVE II. Stephan Windecker

SKG Congress, 2015 EVOLVE II. Stephan Windecker SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,

More information

Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry

Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry < An appendix is published online only. To view these files please visit the journal online (http://heart.bmj.com). 1 Barts and The London National Health Service Trust, London, UK 2 Heart Institute, Hadassah-Hebrew

More information

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts

More information

A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents

A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents ISPUB.COM The Internet Journal of Cardiology Volume 3 Number 2 A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents M Sondhi, A Jagannath, J

More information

Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease

Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease Jeong Hoon Yang, MD, Hyeon-Cheol Gwon, MD, Soo Jin Cho, MD, Joo

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

Medicine OBSERVATIONAL STUDY

Medicine OBSERVATIONAL STUDY Medicine OBSERVATIONAL STUDY It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent Ju-Youn Kim,

More information

Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization

Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023

More information

2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice

2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023

More information

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang

More information

Outcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial

Outcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial Journal of the American College of Cardiology Vol. 45, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074

More information

Significant Reduction in Restenosis After the Use of Sirolimus-Eluting Stents in the Treatment of Chronic Total Occlusions

Significant Reduction in Restenosis After the Use of Sirolimus-Eluting Stents in the Treatment of Chronic Total Occlusions Journal of the American College of Cardiology Vol. 43, No. 11, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.045

More information

Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance

Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Richard Kuntz Brigham and Women s s Hospital Harvard Medical School Late Loss and DES Brief history of Late Loss

More information

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute

More information

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,

More information

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,

More information

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,

More information

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:

More information